Sugi Predict

Sugi Predict / Compounds / SCHEMBL5203487

SCHEMBL5203487

SCHEMBL5203487

Cc1c(N)cc(Br)cc1[N+](=O)[O-]

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.52
▸ TSHR P16473 3/20 0.47
▸ TDP1 Q9NUW8 6/20 0.44
▸ ALDH1A1 P00352 5/20 0.44
▸ CYP3A4 P08684 4/20 0.44
▸ RECQL P46063 1/20 0.43
▸ ERN1 O75460 1/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ CCR6 P51684 1/20 0.40
▸ S100A4 P26447 1/20 0.39
▸ TRPV1 Q8NER1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5201165 0.86 CYP1A2 (0.61) CYP1A2TSHRTDP1ALDH1A1CYP3A4
SCHEMBL1281710 0.82 ALDH1A1 (0.56) TSHRTDP1ALDH1A1CYP3A4ERN1
SCHEMBL30855983 0.81 CYP1A2 (0.67) CYP1A2TSHRTDP1ALDH1A1CYP3A4
SCHEMBL1330407 0.80 TSHR (0.55) CYP1A2TSHRTDP1ALDH1A1CYP3A4
SCHEMBL259813 0.80 TSHR (0.60) CYP1A2TSHRTDP1ALDH1A1CYP3A4
SCHEMBL629679 0.80 TSHR (0.55) CYP1A2TSHRTDP1ALDH1A1CYP3A4
SCHEMBL13280627 0.80 CYP1A2 (0.66) CYP1A2TSHRTDP1ALDH1A1CYP3A4
SCHEMBL629542 0.80 CYP1A2 (0.55) CYP1A2TSHRTDP1ALDH1A1CYP3A4
SCHEMBL221077 0.79 ALDH1A1 (0.57) CYP1A2TSHRTDP1ALDH1A1CYP3A4
SCHEMBL938651 0.78 GPR35 (0.61) CYP1A2TSHRTDP1ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2025-02-25 — — US disclosed
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-10-24 — — US disclosed
US-20240043441-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-02-08 — — US disclosed
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2024-01-23 — — US disclosed
CN-117088847-A Preparation, application and application of fused ring compound 上海济煜医药科技有限公司 2023-11-21 — — CN disclosed
CN-111253397-B MNK inhibitors 上海迪诺医药科技有限公司 2023-11-14 — — CN disclosed
CN-116947856-A EZH2 inhibitor and preparation method and application thereof 星希尔生物科技(上海)有限公司 2023-10-27 — — CN disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 — — US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 — — US disclosed
US-20230212183-A9 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-07-06 — — US disclosed
EP-1765330-A2 PYRANOINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION OR DISEASE Viropharma Incorporated (US) 2007-03-28 — — EP disclosed
CN-1262547-C Phenyl-and aminophenyl-alkyl sulfonamide and urea derivative HOFFMANN LA ROCHE (CH) 2006-07-05 — — CN disclosed
WO-2005084315-A2 PYRANOINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION OR DISEASE VIROPHARMA INCORPORATED (US) 2005-09-15 — — WO disclosed
CN-1176910-C Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives - 2004-11-24 — — CN disclosed
CN-1515559-A Phenyl-and aminophenyl-alkyl sulfonamide and urea derivative - 2004-07-28 — — CN disclosed
CN-1515562-A Phenyl-and aminophenyl-alkyl sulfonamide and urea derivative - 2004-07-28 — — CN disclosed
US-6057349-A ALPHA.SUB.1A/1L AGONISTS USED IN THE TREATMENT OF VARIOUS DISEASE STATES SUCH AS URINARY INCONTINENCE, NASAL CONGESTION, PRIAPISM, DEPRESSION, ANXIETY, DEMENTIA, SENILITY, ALZHEIMER'S, DEFICIENCIES IN ATTENTIVENESS AND COGNITION, AND F. HOFFMAN LA ROCHE AG (CH) 2000-05-02 — — US disclosed
US-5952362-A INHIBITOR OF GLYCOGEN PHOSPHORYLASE ENZYMETIC ACTIVITY AND GLUCOSE ACITIVITY SYNTEX (U.S.A) INC. (US) 1999-09-14 — — US disclosed
EP-0887346-A2 Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives, their preparation and their use as alpha1A/1L adrenoceptor agonists F. HOFFMANN-LA ROCHE AG (CH) 1998-12-30 — — EP disclosed
CN-1203228-A Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives HOFFMANN LA ROCHE (CH) 1998-12-30 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C KRAS, NRAS, HRAS CYP1A2 4341/4885TSHR 1809/4885TDP1 3784/4885
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C KRAS, NRAS, HRAS CYP1A2 1845/4885TSHR 2014/4885TDP1 2228/4885
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS CYP1A2 1845/4885TSHR 2014/4885TDP1 2228/4885
US-20230212183-A9 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS CYP1A2 3408/4885TSHR 1662/4885TDP1 2242/4885
US-20240043441-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS CYP1A2 3408/4885TSHR 1662/4885TDP1 2242/4885
US-20230303586-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS CYP1A2 3408/4885TSHR 1662/4885TDP1 2242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.